DIEBOLD NIXDORF INC (DBD) Stock Fundamental Analysis
USA - New York Stock Exchange - NYSE:DBD - US2536512021 - Common Stock
65.38 USD
+0.05 (+0.08%)
65.38 USD
0 (0%)
Overall DBD gets a fundamental rating of 4 out of 10. We evaluated DBD against 35 industry peers in the Technology Hardware, Storage & Peripherals industry. DBD has only an average score on both its financial health and profitability. DBD has a correct valuation and a medium growth rate.
1. Profitability
1.1 Basic Checks
DBD had positive earnings in the past year.
In the past year DBD had a positive cash flow from operations.
In the past 5 years DBD reported 4 times negative net income.
In multiple years DBD reported negative operating cash flow during the last 5 years.
1.2 Ratios
Looking at the Return On Assets, with a value of 1.36%, DBD is in line with its industry, outperforming 60.00% of the companies in the same industry.
DBD's Return On Equity of 4.57% is fine compared to the rest of the industry. DBD outperforms 71.43% of its industry peers.
Looking at the Return On Invested Capital, with a value of 8.85%, DBD is in the better half of the industry, outperforming 71.43% of the companies in the same industry.
DBD had an Average Return On Invested Capital over the past 3 years of 5.12%. This is significantly below the industry average of 15.30%.
The 3 year average ROIC (5.12%) for DBD is below the current ROIC(8.85%), indicating increased profibility in the last year.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 1.36% | ||
| ROE | 4.57% | ||
| ROIC | 8.85% |
ROA(3y)4.54%
ROA(5y)0.8%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)5.12%
ROIC(5y)5.58%
1.3 Margins
The Profit Margin of DBD (1.37%) is comparable to the rest of the industry.
DBD has a Operating Margin of 7.47%. This is in the better half of the industry: DBD outperforms 77.14% of its industry peers.
DBD's Operating Margin has improved in the last couple of years.
DBD has a Gross Margin of 25.48%. This is in the lower half of the industry: DBD underperforms 60.00% of its industry peers.
In the last couple of years the Gross Margin of DBD has remained more or less at the same level.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 7.47% | ||
| PM (TTM) | 1.37% | ||
| GM | 25.48% |
OM growth 3Y20.78%
OM growth 5Y40.66%
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-2.32%
GM growth 5Y0.68%
2. Health
2.1 Basic Checks
DBD has a Return on Invested Capital (ROIC), which is below the Cost of Capital (WACC), which means it is destroying value.
DBD has about the same amout of shares outstanding than it did 1 year ago.
Compared to 5 years ago, DBD has less shares outstanding
The debt/assets ratio for DBD has been reduced compared to a year ago.
2.2 Solvency
DBD has an Altman-Z score of 1.94. This is not the best score and indicates that DBD is in the grey zone with still only limited risk for bankruptcy at the moment.
DBD has a Altman-Z score of 1.94. This is comparable to the rest of the industry: DBD outperforms 48.57% of its industry peers.
DBD has a debt to FCF ratio of 3.71. This is a good value and a sign of high solvency as DBD would need 3.71 years to pay back of all of its debts.
DBD has a better Debt to FCF ratio (3.71) than 68.57% of its industry peers.
A Debt/Equity ratio of 0.84 indicates that DBD is somewhat dependend on debt financing.
DBD has a Debt to Equity ratio of 0.84. This is in the lower half of the industry: DBD underperforms 60.00% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.84 | ||
| Debt/FCF | 3.71 | ||
| Altman-Z | 1.94 |
ROIC/WACC0.94
WACC9.39%
2.3 Liquidity
A Current Ratio of 1.36 indicates that DBD should not have too much problems paying its short term obligations.
DBD has a Current ratio (1.36) which is comparable to the rest of the industry.
A Quick Ratio of 0.89 indicates that DBD may have some problems paying its short term obligations.
With a Quick ratio value of 0.89, DBD perfoms like the industry average, outperforming 54.29% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 1.36 | ||
| Quick Ratio | 0.89 |
3. Growth
3.1 Past
The earnings per share for DBD have decreased strongly by -38.07% in the last year.
DBD shows a strong growth in Earnings Per Share. Measured over the last years, the EPS has been growing by 69.69% yearly.
The Revenue has decreased by -2.86% in the past year.
DBD shows a decrease in Revenue. Measured over the last years, the Revenue has been decreasing by -3.18% yearly.
EPS 1Y (TTM)-38.07%
EPS 3Y69.69%
EPS 5YN/A
EPS Q2Q%150.91%
Revenue 1Y (TTM)-2.86%
Revenue growth 3Y-1.33%
Revenue growth 5Y-3.18%
Sales Q2Q%1.95%
3.2 Future
Based on estimates for the next years, DBD will show a quite strong growth in Earnings Per Share. The EPS will grow by 19.21% on average per year.
The Revenue is expected to grow by 2.51% on average over the next years.
EPS Next Y8.85%
EPS Next 2Y12.85%
EPS Next 3Y19.21%
EPS Next 5YN/A
Revenue Next Year1.72%
Revenue Next 2Y1.93%
Revenue Next 3Y2.51%
Revenue Next 5YN/A
3.3 Evolution
The estimated forward EPS growth is still strong, although it is decreasing when compared to the stronger growth in the past years.
The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.
4. Valuation
4.1 Price/Earnings Ratio
The Price/Earnings ratio is 17.86, which indicates a rather expensive current valuation of DBD.
DBD's Price/Earnings ratio is a bit cheaper when compared to the industry. DBD is cheaper than 77.14% of the companies in the same industry.
The average S&P500 Price/Earnings ratio is at 26.49. DBD is valued slightly cheaper when compared to this.
DBD is valuated correctly with a Price/Forward Earnings ratio of 13.30.
DBD's Price/Forward Earnings ratio is a bit cheaper when compared to the industry. DBD is cheaper than 65.71% of the companies in the same industry.
DBD is valuated rather cheaply when we compare the Price/Forward Earnings ratio to 23.69, which is the current average of the S&P500 Index.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 17.86 | ||
| Fwd PE | 13.3 |
4.2 Price Multiples
DBD's Enterprise Value to EBITDA ratio is rather cheap when compared to the industry. DBD is cheaper than 94.29% of the companies in the same industry.
DBD's Price/Free Cash Flow ratio is rather cheap when compared to the industry. DBD is cheaper than 82.86% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 9.32 | ||
| EV/EBITDA | 7.3 |
4.3 Compensation for Growth
The high PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates an expensive valuation of the company.
DBD's earnings are expected to grow with 19.21% in the coming years. This may justify a more expensive valuation.
PEG (NY)2.02
PEG (5Y)N/A
EPS Next 2Y12.85%
EPS Next 3Y19.21%
5. Dividend
5.1 Amount
No dividends for DBD!.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
65.38
+0.05 (+0.08%)
Chartmill FA Rating
GICS SectorInformation Technology
GICS IndustryGroupTechnology Hardware & Equipment
GICS IndustryTechnology Hardware, Storage & Peripherals
Earnings (Last)
Earnings (Next)
Inst Owners105.36%
Inst Owner Change-2.66%
Ins Owners1.82%
Ins Owner Change0%
Market Cap2.35B
Revenue(TTM)3.69B
Net Income(TTM)50.60M
Analysts82.86
Price Target80.58 (23.25%)
Short Float %2.16%
Short Ratio4.21
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DP0%
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)52.97%
Min EPS beat(2)46.39%
Max EPS beat(2)59.55%
EPS beat(4)3
Avg EPS beat(4)24.69%
Min EPS beat(4)-8.92%
Max EPS beat(4)59.55%
EPS beat(8)6
Avg EPS beat(8)71.52%
EPS beat(12)8
Avg EPS beat(12)-72.18%
EPS beat(16)9
Avg EPS beat(16)-86.09%
Revenue beat(2)1
Avg Revenue beat(2)1.41%
Min Revenue beat(2)-0.2%
Max Revenue beat(2)3.02%
Revenue beat(4)1
Avg Revenue beat(4)0.15%
Min Revenue beat(4)-1.34%
Max Revenue beat(4)3.02%
Revenue beat(8)4
Avg Revenue beat(8)0.31%
Revenue beat(12)4
Avg Revenue beat(12)-0.58%
Revenue beat(16)4
Avg Revenue beat(16)-1.83%
PT rev (1m)4.41%
PT rev (3m)4.41%
EPS NQ rev (1m)0.83%
EPS NQ rev (3m)11.47%
EPS NY rev (1m)13.35%
EPS NY rev (3m)20.23%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)0.09%
Revenue NY rev (1m)-0.36%
Revenue NY rev (3m)-0.36%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 17.86 | ||
| Fwd PE | 13.3 | ||
| P/S | 0.64 | ||
| P/FCF | 9.32 | ||
| P/OCF | 8.39 | ||
| P/B | 2.12 | ||
| P/tB | N/A | ||
| EV/EBITDA | 7.3 |
EPS(TTM)3.66
EY5.6%
EPS(NY)4.92
Fwd EY7.52%
FCF(TTM)7.01
FCFY10.73%
OCF(TTM)7.79
OCFY11.91%
SpS102.88
BVpS30.87
TBVpS-9.56
PEG (NY)2.02
PEG (5Y)N/A
Graham Number50.42
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 1.36% | ||
| ROE | 4.57% | ||
| ROCE | 11.2% | ||
| ROIC | 8.85% | ||
| ROICexc | 9.91% | ||
| ROICexgc | 29.15% | ||
| OM | 7.47% | ||
| PM (TTM) | 1.37% | ||
| GM | 25.48% | ||
| FCFM | 6.82% |
ROA(3y)4.54%
ROA(5y)0.8%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)5.12%
ROIC(5y)5.58%
ROICexc(3y)6.13%
ROICexc(5y)6.88%
ROICexgc(3y)21.8%
ROICexgc(5y)29.05%
ROCE(3y)6.48%
ROCE(5y)7.06%
ROICexgc growth 3Y-11.73%
ROICexgc growth 5Y37.89%
ROICexc growth 3Y4.77%
ROICexc growth 5Y35.34%
OM growth 3Y20.78%
OM growth 5Y40.66%
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-2.32%
GM growth 5Y0.68%
F-Score7
Asset Turnover0.99
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.84 | ||
| Debt/FCF | 3.71 | ||
| Debt/EBITDA | 2.28 | ||
| Cap/Depr | 20.59% | ||
| Cap/Sales | 0.75% | ||
| Interest Coverage | 2.89 | ||
| Cash Conversion | 68.06% | ||
| Profit Quality | 497.23% | ||
| Current Ratio | 1.36 | ||
| Quick Ratio | 0.89 | ||
| Altman-Z | 1.94 |
F-Score7
WACC9.39%
ROIC/WACC0.94
Cap/Depr(3y)16.93%
Cap/Depr(5y)15.92%
Cap/Sales(3y)0.61%
Cap/Sales(5y)0.61%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-38.07%
EPS 3Y69.69%
EPS 5YN/A
EPS Q2Q%150.91%
EPS Next Y8.85%
EPS Next 2Y12.85%
EPS Next 3Y19.21%
EPS Next 5YN/A
Revenue 1Y (TTM)-2.86%
Revenue growth 3Y-1.33%
Revenue growth 5Y-3.18%
Sales Q2Q%1.95%
Revenue Next Year1.72%
Revenue Next 2Y1.93%
Revenue Next 3Y2.51%
Revenue Next 5YN/A
EBIT growth 1Y-5.55%
EBIT growth 3Y19.17%
EBIT growth 5Y36.19%
EBIT Next Year24.55%
EBIT Next 3Y14.01%
EBIT Next 5YN/A
FCF growth 1Y171.3%
FCF growth 3Y8.67%
FCF growth 5Y113.09%
OCF growth 1Y186.31%
OCF growth 3Y6.68%
OCF growth 5Y26.59%
DIEBOLD NIXDORF INC / DBD FAQ
What is the fundamental rating for DBD stock?
ChartMill assigns a fundamental rating of 4 / 10 to DBD.
What is the valuation status for DBD stock?
ChartMill assigns a valuation rating of 5 / 10 to DIEBOLD NIXDORF INC (DBD). This can be considered as Fairly Valued.
What is the profitability of DBD stock?
DIEBOLD NIXDORF INC (DBD) has a profitability rating of 4 / 10.
How financially healthy is DIEBOLD NIXDORF INC?
The financial health rating of DIEBOLD NIXDORF INC (DBD) is 4 / 10.
Can you provide the dividend sustainability for DBD stock?
The dividend rating of DIEBOLD NIXDORF INC (DBD) is 0 / 10 and the dividend payout ratio is 0%.